The FDA has approved an Emergent BioSolutions vaccine, ACAM2000, for preventing infection from the mpox virus, which is related to smallpox. This vaccine was originally developed to protect against smallpox and is now approved for preventing mpox in high-risk individuals. The ACAM2000 vaccine uses a live vaccinia virus to stimulate the immune system to produce protective antibodies. The current mpox outbreak in Africa is caused by a severe variant of the virus, leading to a higher risk of death. Emergent is working with global health authorities to address the outbreak and has donated 50,000 doses of the vaccine for potential deployment in Central Africa.
Source link
FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox
